Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immuron Limited ( (AU:IMC) ) has shared an update.
Immuron Limited has announced its 2025 Annual General Meeting, scheduled for November 11, 2025, in Melbourne. The meeting will address several key resolutions, including the adoption of the Remuneration Report and the re-election of two directors, Prof Ravi Savarirayan and Mr Paul Brennan. Shareholders can attend in person or virtually, although virtual attendees will not be able to vote. This meeting is significant for stakeholders as it will determine leadership continuity and compensation policies, impacting the company’s strategic direction and governance.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapeutic products for the treatment of gut-mediated diseases. The company is known for its research and development in the field of oral vaccines and immune supplements, targeting both human and animal health markets.
Average Trading Volume: 252,141
Technical Sentiment Signal: Hold
Current Market Cap: A$23.87M
See more insights into IMC stock on TipRanks’ Stock Analysis page.